Link: Basilea’s
“We are pleased to announce the advancement of BAL5788 into phase III clinical trials for the second indication of nosocomial pneumonia in addition to the earlier commenced phase III clinical trials in complicated skin and skin structure infections. Based on its broad Gram-positive and Gram-negative antibiotic profile, including activity on MRSA, its low probability of inducing resistance and its expected cephalosporin-like safety profile, BAL5788 has the potential to become a drug of choice in hospital-acquired pneumonia.
BAL5788 is the first of a new class of broad-spectrum anti-MSRA cephalosporin antibiotics that was specially designed to bind to the penicillin-resistant targets in Gram-positive cocci, resulting in potent bactericidal activity towards methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). BAL5788 not only has maintained a broad-spectrum profile targeting other Gram-positive as well as Gram-negative pathogens, but has also shown a low potential to induce resistance in vitro.
